A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)

被引：0
|
作者：
Hiroyuki Uetake
Masamichi Yasuno
Megumi Ishiguro
Shingo Kameoka
Yasuhiro Shimada
Keiichi Takahashi
Toshiaki Watanabe
Kei Muro
Hideo Baba
Junji Yamamoto
Nobuyuki Mizunuma
Hiroshi Tamagawa
Izumi Mochizuki
Yusuke Kinugasa
Takashi Kikuchi
Kenichi Sugihara
机构：
[1] Tokyo Medical and Dental University,Department of Translational Oncology, Graduate School
[2] Tokyo Metropolitan Hiroo Hospital,Department of Surgery
[3] Tokyo Women’s Medical University,Department of Surgery II
[4] National Cancer Center Hospital,Division of Gastrointestinal Medical Oncology
[5] Tokyo Metropolitan Cancer and Infectious Disease Center,Colorectal Surgical Division, Department of Surgery
[6] Komagome Hospital,Department of Surgical Oncology, Graduate School of Medicine
[7] The University of Tokyo,Clinical Oncology
[8] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery, Graduate School of Medical Science
[9] Kumamoto University,Department of Surgery
[10] National Defense Medical College,Gastroenterological Center
[11] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Surgery
[12] Osaka General Medical Center,Department of Surgery
[13] Iwate Prefectural Central Hospital,Gastrointestinal Surgery Division
[14] Shizuoka Cancer Center,Department of Statistical Analysis
[15] Translational Research Informatics Center,Department of Surgery Oncology
[16] Tokyo Medical and Dental University,undefined
来源：
Annals of Surgical Oncology | 2015年 / 22卷
关键词：
Bevacizumab; Liver Metastasis; Sixth Cycle; Resectable Liver Metastasis; High Adverse Event;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：908 / 915
页数：7
相关论文
共 50 条
  • [21] Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection
    Dewdney, A.
    Cunningham, D.
    Barbachano, Y.
    Chau, I.
    BRITISH JOURNAL OF CANCER, 2012, 106 (11) : 1718 - 1721
  • [22] Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial
    Tang, Wentao
    Ren, Li
    Liu, Tianshu
    Ye, Qinghai
    Wei, Ye
    He, Guodong
    Lin, Qi
    Wang, Xiaoying
    Wang, Mingliang
    Liang, Fei
    Cui, Yuehong
    Xu, Jianmin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) : 3175 - +
  • [23] Conversion Chemotherapy Using Cetuximab plus FOLFIRI Followed by Bevacizumab plus mFOLFOX6 in Patients with Unresectable Liver Metastases from Colorectal Cancer
    Uehara, Keisuke
    Ishiguro, Seiji
    Hiramatsu, Kazuhiro
    Nishio, Hideki
    Takeuchi, Eiji
    Takahari, Daisuke
    Yoshioka, Yuichiro
    Takahashi, Yu
    Ebata, Tomoki
    Yoshimura, Kenichi
    Muro, Kei
    Nagino, Masato
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (10) : 1229 - 1232
  • [24] A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
    Van Cutsem, E.
    Prenen, H.
    D'Haens, G.
    Bennouna, J.
    Carrato, A.
    Ducreux, M.
    Bouche, O.
    Sobrero, A.
    Latini, L.
    Staines, H.
    Oum'Hamed, Z.
    Dressler, H.
    Studeny, M.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2085 - 2091
  • [25] Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
    Keisuke Miwa
    Eiji Oki
    Yasunori Emi
    Hiroshi Saeki
    Tetsuya Kusumoto
    Yoshito Akagi
    Yutaka Ogata
    Hironori Samura
    Shoji Tokunaga
    Hiroshi Ishikawa
    Takaho Tanaka
    Susumu Sueyoshi
    Hidefumi Higashi
    Hiroyuki Matsuda
    Tetsuo Touyama
    Yoshihiko Maehara
    International Journal of Clinical Oncology, 2016, 21 : 110 - 117
  • [26] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
    van Hazel, Guy A.
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget A.
    Strickland, Andrew H.
    Ferguson, Tom
    Rodriguez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan
    Boucher, Eveline
    Tichler, Thomas
    Shacham-Shmueli, Einat
    Powell, Alex
    Eliadis, Paul
    Isaacs, Richard
    Price, David
    Moeslein, Fred
    Taieb, Julien
    Bower, Geoff
    Gebski, Val
    Van Buskirk, Mark
    Cade, David N.
    Thurston, Kenneth
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1723 - +
  • [27] Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
    Miwa, Keisuke
    Oki, Eiji
    Emi, Yasunori
    Saeki, Hiroshi
    Kusumoto, Tetsuya
    Akagi, Yoshito
    Ogata, Yutaka
    Samura, Hironori
    Tokunaga, Shoji
    Ishikawa, Hiroshi
    Tanaka, Takaho
    Sueyoshi, Susumu
    Higashi, Hidefumi
    Matsuda, Hiroyuki
    Touyama, Tetsuo
    Maehara, Yoshihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (01) : 110 - 117
  • [28] A multicenter phase II trial to assess the efficacy and safety of bevacizumab plus mFOLFOX6 as induction chemotherapy toward R0 surgical resection in advanced colorectal liver metastases with mutant-type KRAS: NEXTO-mt trial
    Watanabe, Genki
    Mise, Yoshihiro
    Oba, Masaru
    Saiura, Akio
    Inoue, Yosuke
    Takahashi, Yu
    Kishi, Yoji
    Suyama, Koichi
    Takayama, Tadatoshi
    Noie, Tamaki
    Nishioka, Yujiro
    Akamatsu, Nobuhisa
    Arita, Junichi
    Kokudo, Norihiro
    Hasegawa, Kiyoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [29] Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
    Gruenberger, T.
    Bridgewater, J.
    Chau, I.
    Garcia Alfonso, P.
    Rivoire, M.
    Mudan, S.
    Lasserre, S.
    Hermann, F.
    Waterkamp, D.
    Adam, R.
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 702 - 708
  • [30] Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
    Leitner, Harald
    TUMORBOARD, 2015, 4 (01): : 16 - 17
12345